BindingDB logo
myBDB logout

26 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26288158 13 Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes.EBI University of Michigan
25358116 84 Synthesis of 7-halogenated isatin sulfonamides: nonradioactive counterparts of caspase-3/-7 inhibitor-based potential radiopharmaceuticals for molecular imaging of apoptosis.EBI Westf£lische Wilhelms-Universit£t M£nster
23411396 60 Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: nonradioactive counterparts of putative PET-compatible apoptosis imaging agents.EBI Westf£lische Wilhelms-Universit£t M£nster
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
14980679 30 Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid.EBI Maxim Pharmaceuticals
21441025 147 Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.EBI Washington University School of Medicine
19908842 84 Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.EBI National Human Genome Research Institute
19445513 82 Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis.EBI Westfalische Wilhelms-Universitat
19049429 70 Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide.EBI Imperial College London
17889532 23 Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P(2) amino acid by 2-aminoaryl acids and other non-natural amino acids.EBI EpiCept Corporation
17585855 65 Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors.EBI Washington University School of Medicine
17181147 10 Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.EBI University of Edinburgh
17154501 121 5-pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis.EBI University Hospital of the Westfälische Wilhelms-Universität
16891117 5 Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis.EBI Washington University School of Medicine
15713391 19 Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 alpha-amino acid by a alpha-hydroxy acid.EBI Maxim Pharmaceuticals
15686936 210 Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.EBI Merck Frosst Centre for Therapeutic Research
15109679 15 Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.EBI Idun Pharmaceuticals, Inc.
12270186 99 Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.EBI Idun Pharmaceuticals, Inc.
12270185 257 Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization.EBI Idun Pharmaceuticals, Inc.
19326941 104 Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6.BDB Washington University
16302804 145 N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies.BDB Washington University School of Medicine
11384246 86 Potent and selective nonpeptide inhibitors of caspases 3 and 7.BDB GlaxoSmithKline
16509578 79 Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.BDB Shanghai Institutes for Biological Sciences
12408711 112 Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.BDB Sunesis Pharmaceuticals